Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — H1 FY2024 Earnings Presentation
12 slides from Little Green Pharma's earnings presentation, Nov 30, 2023
Slide 1: Half Yearly Financial Presentation November 2023
Half Yearly For personal use only Financial ASX:LGP presentation November 2023 The most trusted medicinal cannabis brand
Slide 2: Disclaimer
Disclaimer Disclaimer Not financial product advice For personal use only This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 215) (“LGP”) and its This document does not constitute financial product advice or take into account your investment objectives, taxation
Slide 3: Agenda
SECTION ONE Agenda For personal use only Financial performance • Financial highlights • Revenue growth • Balance sheet Outlook and focus areas • Short-term outlook and long-term fundamentals • Focus areas for FY2024 3
Slide 4: Financial Performance
SECTION ONE For personal use only Financial Performance 4
Slide 5: Financial Highlights
HIGHLIGHTS Financial For personal use only GROSS MARGIN BEFORE FAIR ADJUSTED EBITDA* TOTAL REVENUE VALUE ADJUSTMENTS 112% 40% 10% from a loss of $5.9m increase from increase from to positive $0.7m $9.2m to $12.8m $5.1m to $5.6m NET TANGIBLE ASSET LOSS AFTER TAX LONG TERM DEBT BACKING 72% 64% 7% from
Slide 6: Revenue Metrics: Revenue Growth
REVENUE METRICS REVENUE GROWTH ($m) Strong revenue 30-Sep-22 30-Sep-23 growth For personal use only 12.54 Strong revenue growth with an 9.16 increase of 37% compared to the 7.56 prior comparative period, and an increase of 40% when taking into account the $250,000 revenue 5.03 associated with the as
Slide 7: Our diversified quality revenue base
REVENUE METRICS Our diversified quality revenue base For personal use only • Australian revenue of $10.8m up BY PRODUCT BY CUSTOMER PRODUCT MIX PRODUCT MIX 36% compared to prior LOCATION AUSTRALIA EUROPE comparative period • European revenue of $2.0m up 61% compared to prior comparative period • Flo
Slide 8: Balance sheet
BALANCE SHEET Balance sheet For personal use only • Cash of $6.2m with net current assets of $20.3m • Long term debt down from $9.7m to $3.5m after: • repayment of $4.1m to Canopy Growth Inc in relation to acquisition of Danish facility leaving facility debt free • disposal of two properties adjacen
Slide 9: Outlook and focus areas for FY2024
SECTION TWO For personal use only Outlook and focus areas for FY2024 9
Slide 10: Outlook
MARKET OUTLOOK Outlook LONG TERM FUNDAMENTALS For personal use only • Excellent Australian in-market brand and reputation SHORT TERM • Number one oil supplier in Australia Australia • Globally leading European market access and • Continued strong market growth distribution partner networks • Market
Slide 11: Focus areas for FY2024
FOCUS AREAS Focus areas for FY2024 For personal use only • Drive revenue growth through expansion and diversification of product offering • Acquire additional sales channels to increase Danish facility utilisation and drive further economies of scale • Expand supply into France, Poland and the UK •
Slide 12: Thank you
For personal use only Thank you 12
Little Green Pharma — H1 FY2024 Earnings Presentation on 6ix